Page 561 - Williams Hematology ( PDFDrive )

536 Part VI: The Erythrocyte Chapter 35: Aplastic Anemia: Acquired and Inherited 537

199. Teramura M, Kimura A, Iwase S, et al: Treatment of severe aplastic anemia with anti- 230. Desmond R, Townsley DM, Dunbar C, Young NS. Eltrombopag in aplastic anemia.
thymocyte globulin and cyclosporin A with or without G-CSF in adults: A multicenter Semin Hematol 52:31, 2015.
randomized study in Japan. Blood 110:1756, 2007. 231. Speck B, Tichelli A, Widmer E, et al: Splenectomy as an adjuvant measure in the treat-
200. Bacigalupo A, Brand R, Oneto R, et al: Treatment of acquired severe aplastic anemia: ment of severe aplastic anaemia. Br J Haematol 92:818, 1996.
Bone marrow transplantation compared with immunosuppressive therapy—The Euro- 232. Sadowitz PD, Dubowy RL: Intravenous immunoglobulin in the treatment of aplastic
pean Group for Blood and Marrow Transplantation experience. Semin Hematol 37:69, anemia. Am J Pediatr Hematol Oncol 12:198, 1990.
2000. 233. Bodenstein H: Successful treatment of aplastic anemia with high-dose immunoglobu-
201. Gillio AP, Boulad F, Small TN, et al: Comparison of long-term outcome of children with lin [letter]. N Engl J Med 314:1368, 1991.
severe aplastic anemia treated with immunosuppression versus bone marrow trans- 234. Ito T, Haraiwa M, Ishikawa Y, et al: Lymphocytapheresis in a patient with severe aplastic
plantation. Biol Blood Marrow Transplant 3:18, 1997. anaemia. Acta Haematol 80:167, 1988.
202. De Planque MM, Kluin-Nelemans HC, Van Krieken HJM, et al: Evolution of acquired 235. Morales-Polanco MR, Sanchez-Valle E, Guerrero-Rivera S, et al: Treatment results of 23
severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. Br J cases of severe aplastic anemia with lymphocytapheresis. Arch Med Res 28:85, 1997.
Haematol 70:55, 1988. 236. Tiu RV, Visconte V, Elson P, et al: LFA-3/CD2 pathway, potential target for immuno-
203. Tichelli A, Gratwohl A, Würsch A, et al: Late haematological complications in severe suppressive therapy in aplastic anemia: A phase I/II clinical trail of alefacept in patients
aplastic anaemia. Br J Haematol 69:413, 1988. with relapsed/ refractory aplastic anemia. Blood 122: abstract 3711, 2013.
204. Moore MAS, Castro-Malaspina H: Immunosuppression in aplastic anemia—Postpon- 237. Kiem HP, McDonald GB, Myerson D, et al: Marrow transplantation for hepatitis-
ing the inevitable? N Engl J Med 314:1358, 1991. associated aplastic anemia: A follow-up of long-term survivors. Biol Blood Marrow
205. Tichelli A, Passweg J, Nissen C, et al: Repeated treatment with horse antilymphocyte Transplant 2:93, 1996.
globulin for severe aplastic anaemia. Br J Haematol 100:393, 1998. 238. Lewis SM: Course and prognosis in aplastic anemia. Br Med J 1:1027, 1965.
206. Scheinberg P, Nunez O, Young NS: Retreatment with rabbit anti-thymocyte globulin 239. Lynch RE, Williams DM, Reading JC, Cartwright GE: The prognosis in aplastic anemia.
and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Blood 45:517, 1975.
Haematol 133:622, 2006. 240. Horowitz MM: Current status of allogeneic bone marrow transplantation in acquired
207. Scheinberg P, Nunez O, Weinstein B, et al: Activity of alemtuzumab monotherapy aplastic anemia. Semin Hematol 37:30, 2000.
in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 241. Ades L, Mary J-Y, Robin M, et al: Long-term outcome after bone marrow transplanta-
119:345, 2011. tion for severe aplastic anemia. Blood 103:2490, 2004.
208. Marsh JC, Kulasekararaj AG: Management of the refractory aplastic anemia patient: 242. Sangiolo D, Storb R, Deeg HJ, et al: Outcome of allogeneic hematopoietic cell trans-
What are the options? Hematology Am Soc Hematol Educ Program 2013:87, 2013. plantation from HLA-identical siblings for severe aplastic anemia in patients over
209. Risitano AM, Schrezenmeier H: Alternative immunosuppression in patients failing 40 years of age. Biol Blood Marrow Transplant 16:1411, 2010.
immunosuppression with ATG who are not transplant candidates: Campath (Alemtu- 243. Schrezenmeier H, Passweg JR, Marsh JC, et al: Worse outcome and more chronic
zumab). Bone Marrow Transplant 48:186, 2013. GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sib-
210. Bacigalupo A, Van Lint MT, Cerri R, et al: Treatment of severe aplastic anemia with ling donor transplants for young patients with severe acquired aplastic anemia. Blood
bolus 6-methylprednisolone and antilymphocyte globulin. Blut 41:168, 1980. 110:1397, 2007.
211. Issaragrisil S, Tangnai-Trisorana Y, Siriseriwan T, et al: Methylprednisolone therapy 244. Locasciulli A: Acquired aplastic anemia in children: Incidence, prognosis and treat-
in aplastic anaemia: Correlation of in vitro tests and lymphocyte subsets with clinical ment options. Paediatr Drugs 4:761, 2002.
response. Eur J Haematol 40:343, 1988. 245. Scheinberg P, Wu CO, Nunez O, Young NS: Predicting response to immunosuppressive
212. Brodsky RA, Sensenbrenner LL, Jones RJ: Complete remission in severe aplastic ane- therapy and survival in severe aplastic anaemia. Br J Haematol 144:206, 2009.
mia after high-dose cyclophosphamide without bone marrow transplantation. Blood 246. Scheinberg P, Wu CO, Nunez O, Young NS: Long-term outcome of pediatric patients
87:491, 1996. with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J
213. Jones RJ, Barber JP, Vala MS, et al: Assessment of aldehyde dehydrogenase in viable Pediatr 153:814, 2008.
cells. Blood 85:2742, 1995. 247. Tisdale JF, Dunn DE, Maciejewski J: Cyclophosphamide and other new agents for the
214. Kastan MB, Schlaffer I, Russo JE, et al: Direct demonstration of aldehyde dehydroge- treatment of severe aplastic anemia. Semin Hematol 37:102, 2000.
nase in human hematopoietic progenitor cells. Blood 75:1947, 1990. 248. Brodsky RA, Chen AR, Dorr D, et al: High-dose cyclophosphamide for severe aplastic
215. Brodsky RA, Sensenbrenner LL, Smith BD, et al: Durable treatment-free remission fol- anemia: Long-term follow-up. Blood 115:2136, 2010.
lowing high-dose cyclophosphamide for previously untreated severe aplastic anemia. 249. Fanconi G: Familiäre infantile perniziosaartige anämie (perniziöses blutbild und kon-
Ann Intern Med 135:477, 2001. stitution). Jahrbuch Kinderheil 117:257, 1927.
216. Brodsky RA: High-dose cyclophosphamide for aplastic anemia and autoimmunity. 250. Rosendorff J, Bernstein R, Macdougall L, Jenkins T: Fanconi anemia: Another disease
Curr Opin Oncol 14:143, 2002. of unusually high prevalence in the Afrikaans population of South Africa. Am J Med
217. Hansen PB, Lauritzen AM: Aplastic anemia successfully treated with rituximab. Am J Genet 27:793, 1987.
Hematol 80:292, 2005. 251. Dokal I, Vulliamy T: Inherited aplastic anaemias/bone marrow failure syndromes.
218. Hansen PB, Lauritzen AM. Aplastic anemia successfully treated with rituximab. Am J Blood Rev 22:141, 2008.
Hematol 80:292, 2005. 252. Garaycoechea JI, Patel KJ: Why does the bone marrow fail in Fanconi anemia? Blood
219. Takamatsu H, Yagasaki H, Takahashi Y, et al: Aplastic anemia successfully treated with 123:26, 2014.
rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker 253. Jacquemont C, Taniguchi T: The Fanconi anemia pathway and ubiquitin. BMC Biochem
for response. Eur J Haematol 86:541, 2011. 22(8 Suppl 1):S10, 2007.
220. Androgen therapy in aplastic anemia: A comparative study of high and low doses of 254. Alter BP, Giri N, Savage SA, et al: Update on inherited bone marrow failure syndromes
4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory (IBMFS). IBMFS Newsletter of the Clinical Genetics Branch, National Cancer Institute.
Anemias. Scand J Haematol 36:346, 1986. P.1, Summer 2008.
221. Champlin RE, Ho WG, Feig SA, et al: Do androgens enhance the response to anti- 255. HGNC: HUGO Gene Nomenclature Committee of the National Human Genome
thymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Research Institute: Fanconi Anemia, complementation groups. Available at: http://
Blood 66:184, 1985. www.genenames.org/genefamilies/fanc (last accessed 16 February 2015).
222. Socie G, Mary JY, Schrezenmeier H, et al: Granulocyte-stimulating factor and severe 256. Somyajit K, Subramanya S, Nagaraju G: Distinct roles of FANCO/RAD51C protein in
aplastic anemia: A survey by the European Group for Blood and Marrow Transplanta- DNA damage signaling and repair. J Biol Chem 287:3366, 2012.
tion (EBMT). Blood 109:2794, 2007. 257. Kashiyama K, Nakazawa Y, Pliz DT, et al: Malfunction of Nuclease ERCC1-XPF results
223. Tichelli A, Schrezenmeier H, Socié G, et al: A randomized controlled study in patients in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmen-
with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), tosa, and Fanconi anemia. Am J Hum Genet 92:807, 2013.
cyclosporine, with or without G-CSF: A study of the SAA Working Party of the Euro- 258. Dufour C, Corcione A, Svahn J, et al: TNF-α and TNF-γ are overexpressed in the bone
pean Group for Blood and Marrow Transplantation. Blood 117:4434, 2011. marrow of Fanconi anemia patients and TNF-α suppresses erythropoiesis in vitro.
224. Ganser A, Lindemann A, Siepelt G, et al: Effects of recombinant human interleukin-3 Blood 102:2053, 2003.
in aplastic anemia. Blood 76:1287, 1990. 259. D’Apolito M, Zelante L, Savoia A: Molecular basis of Fanconi anemia. Haematologica
225. Walsh CE, Liu JM, Anderson SM, et al: A trial of recombinant human interleukin-1 in 83:533, 1998.
patients with severe refractory aplastic anaemia. Br J Haematol 80:106, 1992. 260. Garcia-Higuera I, Kuang Y, D’Andrea AD: The molecular and cellular biology of Fan-
226. Hirao A: TPO signal for stem cell genomic integrity. Blood 123:459, 2014. coni anemia. Curr Opin Hematol 6:83, 1999.
227. de Lavel B, Pawlikowska P, Barbieri D, et al: Thrombopoietin promotes NHEJ DNA 261. Young NA, Alter BP: Aplastic Anemia: Acquired and Inherited. WB Saunders, Philadel-
repair in hematopoietic stem cells through specific activation of Erk and NF-κB path- phia, 1994.
ways and their target, IEX-1. Blood 123:509, 2014. 262. Estren S, Damshek W: Familial hypoplastic anemia of childhood: Report of 8 cases in 2
228. Desmond R, Townsley DM, Dumitriu B, et al: Eltrombopag restores tri-lineage hemato- families with beneficial effects of splenectomy in 1 case. Am J Dis Child 73:671, 1947.
poiesis in refractory severe aplastic anemia which can be sustained on discontinuation 263. Swhimamura A, D’Andrea AD: Subtyping of Fanconi anemia patients: Implications for
of drug. Blood 123:1818, 2014. clinical management. Blood 102:3459, 2003.
229. Olnes MJ, Scheinberg P, Calvo KR, et al: Eltrombopag and improved hematopoiesis in 264. Carreau M, Liu L, Gan OI, et al: Short-term granulocyte colony-stimulating factor
refractory aplastic anemia. N Engl J Med 367:11, 2012; erratum in N Engl J Med 367:284, and erythropoietin treatment enhances hematopoiesis and survival in the mitomycin
2012.

Kaushansky_chapter 35_p0513-0538.indd 536 9/19/15 12:24 AM